Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Talditercept alfa by Biohaven for Spinal Muscular Atrophy (SMA): Likelihood of Approval
Talditercept alfa is under clinical development by Biohaven and currently in Phase III for Spinal Muscular Atrophy (SMA). According to...